Health Canada approves XERMELO™ (telotristat ethyl)

//Health Canada approves XERMELO™ (telotristat ethyl)

Health Canada approves XERMELO™ (telotristat ethyl)

Health Canada approves XERMELO™ (telotristat ethyl) for the treatment of adult patients suffering from refractory carcinoid syndrome diarrhea(1)

“XERMELOTM is a novel, orally administered, inhibitor of the enzyme tryptophan hydroxylase and is designed to reduce the production of serotonin.4 The approval was based on the positive results of the TELESTAR pivotal trial and the TELECAST trial, two phase 3, randomized, placebo-controlled, 12-week trials where the efficacy and the safety of XERMELOTM were demonstrated in carcinoid syndrome patients. Both trials reported statistically significant reductions of bowel movement (BM) frequency compared with placebo and change in u5-HIAA from baseline.5″

READ FULL PRESS RELEASE

By | 2018-10-17T14:45:09+00:00 October 17th, 2018|Treatment News|0 Comments

About the Author:

Leave A Comment